To review information on desloratadine, a nonsedating antihistamine.
DATA SOURCES:
An English-language MEDLINE search was conducted (1966–July 2002). References of identified articles were subsequently reviewed for additional data. Schering Corporation provided unpublished information.
STUDY SELECTION/DATA EXTRACTION:
Articles and abstracts pertaining to desloratadine were considered for inclusion, with emphasis on randomized, placebo-controlled, double-blind trials.
DATA SYNTHESIS:
Desloratadine is approved for the treatment of symptoms associated with seasonal allergic rhinitis (SAR), perennial allergic rhinitis (PAR), and chronic idiopathic urticaria (CIU) in patients aged ≥12 years. In placebo-controlled trials, desloratadine demonstrated superior efficacy as a once-daily treatment of SAR, PAR, and CIU. Data suggest that desloratadine has antiinflammatory and decongestant activity.
CONCLUSIONS:
Desloratadine appears to be a “me-too” agent, with no major differences compared with other second-generation antihistamines.
HowarthPH, SalageanM, DokicD.Allergic rhinitis: not purely a histamine-related disease. Allergy2000; 55 (suppl)64: 7–16.
10.
HenzBM. The pharmacologic profile of desloratadine: a review. Allergy2001; 56 (suppl 65): 7-13.
11.
AnthesJ, EckelS, RichardC, WestRE, GreenfederS, SakujaS, et al. Characterization of desloratadine at the human H1 receptors (abstract). J Allergy Clin Immunol2001; 107 (2, pt 2): S160.
12.
Kleine-TebbeJ, JostiesC, FrankG, StalleickenD, BuschauerA, SchunackW, et al. Inhibition of IgE- and non-IgE-mediated histamine release from human basophil leukocytes in vitro by a histamine H1-antagonist des-ethoxycarbonyl-loratadine. J Allergy Clin Immunol1994; 93: 494-500.
13.
KreutnerW, HeyJA, AnthesJ, BarnettA, YoungS, TozziS.Preclinical pharmacology of desloratadine, a selective and nonsedating histamine H1 receptor antagonist. 1st communication: receptor selectivity, antihistaminic activity, and antiallergenic effects. Arzneimittelforschung2000; 50: 345-52.
14.
LetariO, MiozzoA, FolcoG, BelloniPA, SalaA, RovatiGE, et al. Effects of loratadine on cytostolic Ca2+ levels and leukotriene release: novel mechanism of action independent of the anti-histaminic activity. Eur J Pharmacol1994; 266: 219-27.
15.
AnthesJ, RichardC, WestRE, WilliamsS, GreenfelderS, GilchrestH, et al. Functional characteristics of desloratadine and other antihistamines in a Chinese hamster ovary (CHO) cell line that expresses the cloned human histamine H1 receptor and in human bronchial smooth muscle cells (abstract). J Allergy Clin Immunol2000; 105 (1, pt 2): S385.
16.
GenoveseA, PatellaV, De CrescenzoG, De PaulisA, SpadaroG, MaroneG.Loratadine and desethoxylcarbonyl-loratadine inhibit the immunological release of mediators from human Fc epsilon RI+ cells. Clin Exp Allergy1997; 27: 559-67.
17.
LippertU, MollerA, WelkerP, ArtucM, HenzBM. Inhibition of cytokine secretion from human leukemic mast cells and basophils by H1-and H2-receptor antagonists. Exp Dermatol2000: 118-24.
18.
LippertU, Kruger-KrasagakesS, MollerA, KiesslingU, CzarnetzkiBM. Pharmacological modulation of IL-6 and IL-8 secretion by the H1-antagonist decarboethoxy-loratadine and dexamethasone by human mast and basophilic cell lines. Exp Dermatol1995; 4 (4, pt 2): 272-6.
19.
SchroederT, SchleimerRP, LichtensteinLM, KreutnerW.Inhibition of cytokine generation and mediator release in human basophils with desloratadine. Clin Exp Allergy2001; 31: 1369-77.
20.
VignolaAM, CrampetteL, MondainM, SauvereG, CzarlewskiW, BousquetJ, et al. Inhibitory activity of loratadine and descarboxyloratadine on expression of ICAM-1 and HLA-DR by nasal epithelial cells. Allergy1995; 50: 200-3.
21.
PapiA, PapadopoulosNG, StanciuLA, DegitzK, HolgateST, JohnstonSL. Effect of desloratadine and loratadine on rhinovirus-induced intercellular adhesion molecule 1 upregulation and promoter activation in respiratory epithelial cells. J Allergy Clin Immunol2001; 108: 221-8.
22.
CiprandiG, PronzatoC, PassalaquaG, DanzigM, CanonicaGW. Loratadine treatment of rhinitis due to pollen allergy reduces epithelial ICAM-I expression. Clin Exp Allergy1997; 27: 1175-83.
23.
LeprevostC, CapronM, De Vos C, TomassiniM, CapronAL. Inhibition of eosinophil chemotaxis by new antiallergic compound (cetirizine). Int Arch Allergy Appl Immunol1988; 87: 9-13.
24.
AbdelazizH, DavakuaJL, KhairOA, BayramH, PriorAJ, DaviesRJ. Effect of fexofenadine on eosinophil-induced changes in epithelial permeability and cytokine release from nasal epithelial cells of patients with seasonal allergic rhinitis. J Allergy Clin Immunol1998; 101: 410-20.
25.
AnderssonM, NolteH, BaumgartenC, PipkornU.Suppressive effect of loratadine on allergen-induced histamine release in the nose. Allergy1991; 46: 540-6.
CampbellA, MichelFB, Bremard-OuryC, CrampetteL, BousquetJ.Overview of allergic mechanisms. Ebastine has more than an antihistamine effect. Drugs1996; 52 (suppl 1): 15-9.
28.
NaclerioRM, Kagey-SobotkaA, LichtensteinLM, FreidhoffL, ProudD.Terfenadine, an H1 antihistamine, inhibits histamine release in vivo in the human. Am Rev Respir Dis1990; 142: 167-71.
29.
JacobiHH, SkovPS, PoulsenLK, MallingHJ, MygindN.Histamine and tryptase in nasal lavage fluid after allergen challenge: effect of 1 week of pretreatment with intranasal azelastine or systemic cetirizine. J Allergy Clin Immunol1999; 103 (5, pt 1): 768-72.
30.
BronskyEA, DockhornRJ, MeltzerEO, ShapiroG, BoltanskyH, LaForceC, et al. Fluticasone propionate aqueous nasal spray compared with terfenadine tablets in the treatment of seasonal allergic rhinitis. J Allergy Clin Immunol1996; 97: 915-21.
31.
KlementssonH, AnderssonM, PipkornU.Allergen-induced increase in nonspecific nasal reactivity is blocked by antihistamines without a clear-cut relationship to eosinophil influx. J Allergy Clin Immunol1990; 86 (4, pt 1): 466-72.
32.
RoquetA, RaudJ, HalldenG, van Hage-HamstenM, HedJ, HanssonLO, et al. Effects of loratadine on anti–IgE-induced inflammation, histamine release, and leukocyte recruitment in skin of atopics. Allergy1995; 50: 414-20.
33.
CiprandiG, PronzatoC, RiccaV, VareseP, Del GiaccoGS, CanonicaGW. Terfenadine exerts antiallergic activity reducing ICAM-1 expression on nasal epithelial cells in patients with pollen allergy. Clin Exp Allergy1995; 25: 871-8.
34.
CiprandiG, BuscagliaS, PesceG, PassalacquaG, RihouxJ P, BagnascoM, et al. Cetirizine reduces inflammatory cell recruitment and ICAM-1 (or CD54) expression on conjunctival epithelium in both early- and late-phase reactions after allergen-specific challenge. J Allergy Clin Immunol1995; 95: 612-21.
35.
FadelR, Herpin-RichardN, RihouxJP, HenocqE.Inhibitory effect of cetirizine 2HCl on eosinophil migration in vivo. Clin Allergy1987; 17: 373-9.
36.
BentleyAM, WalkerS, HanotteF, De VosC, DurhamSR. A comparison of the effects of oral cetirizine and inhaled beclomethasone on early and late asthmatic responses to allergen and the associated increase in airways hyperresponsiveness. Clin Exp Allergy1996; 26: 909-17.
NielsenLP, MyginaN, DahlR.Intranasal corticosteroids for allergic rhinitis: superior relief?Drugs2001; 61: 1563-79.
39.
WalshGM. The clinical relevance of the anti-inflammatory properties of antihistamines. Allergy2001; 55: 53-61.
40.
StormsWW. Rethinking our approach to allergic rhinitis management. Ann Allergy Asthma Immunol2002; 88 (suppl): 30-5.
41.
LemanskeRF. A review of the current guidelines for allergic rhinitis and asthma. J Allergy Clin Immunol1998; 101 (2, pt 2): S392-6.
42.
Package insert. Clarinex (desloratadine).Kenilworth, NJ: Schering Corp., February 2002.
43.
GuptaS, PadhiD, BanfieldC, MarburyT, AffrimeMB. The effect of food on the oral bioavailability of desloratadine (abstract). J Allergy Clin Immunol2000; 105 (1, pt 2): S387.
44.
HerronJM, PadhiD, AffrimeMB, GlueP, GuptaS, BanfieldC.Dose-proportionality, linearity, and pharmacokinetics of desloratadine in healthy adults (abstract). J Allergy Clin Immunol2000; 105 (1, pt2): S385.
45.
PadhiD, BanfieldC, GuptaS, GlueP, AffrimeMB. Multiple-dose pharmacokinetics, safety, and tolerance of desloratadine in healthy volunteers (abstract). J Allergy Clin Immunol2000; 105 (1, pt 2): S385.
46.
BanfieldC, GuptaS, AffrimeM, BatraV.Pharmacokinetic equivalence of pediatric dosages of desloratadine syrup in children and standard 5 mg desloratadine tablets in adults (abstract). J Allergy Clin Immunol2002; 109 (2, pt 2): S103.
47.
BareckiME, CascianoCN, JohnsonWW, ClementRP. In vitro characterization of the inhibition profile of loratadine, desloratadine, and 3-OH-desloratadine for five human cytochrome P450 enzymes. Drug Metab Dispos2001; 29: 1173-5.
48.
Package insert. Claritin (loratadine).Kenilworth, NJ: Schering Corp., September 2000.
49.
RosenbergMA, CohenA, PadhiD, BanfieldC, GuptaS, AffrimeMB. Multiple-dose pharmacokinetics of desloratadine in subjects differing in race and gender (abstract). J Allergy Clin Immunol2000; 105 (1, pt 2): S386.
50.
MeltzerEO, PrennerBM, NayakA, and the Desloratadine Study Group. Efficacy and tolerability of once-daily 5 mg desloratadine, an H1-receptor antagonist, in patients with seasonal allergic rhinitis; assessment during the Spring and Fall allergy seasons. Clin Drug Invest2001; 21: 25-32.
51.
SalmunLM, LoberR, DanzigM, StaudingerH.Efficacy and safety of desloratadine in seasonal allergic rhinitis (abstract). J Allergy Clin Immunol2000; 105 (1, pt 2): S384.
52.
HorakF, StubnerU P, ZieglmayerI, IngD, HarrisAG. Effect of desloratadine versus placebo on nasal airflow and subjective measures of nasal obstruction in subjects with grass pollen-induced allergic rhinitis in an allergen-exposure unit. J Allergy Clin Immunol2002; 109: 956-61.
53.
BechertC.Decongestant efficacy of desloratadine in patients with seasonal allergic rhinitis. Allergy2001; 56: 14-20.
54.
NayakA, LorbertR, SalmanLM. Decongestant effects of desloratadine in patients with seasonal allergic rhinitis (abstract). J Allergy Clin Immunol2000; 105 (1, pt 2): S384.
55.
NayakAS, SchenkelE.Desloratadine reduces nasal congestion in patients with intermittent allergic rhinitis. J Allergy Clin Immunol2001; 56: 1077-80.
56.
ShapiroGG, the Desloratadine Study Group. Decongestant effects of desloratadine in patients with seasonal allergic rhinitis and asthma (abstract). J Allergy Clin Immunol2001; 107: S161.
57.
SchenkelE, CorrenJ, MurrayJJ. Fixed-dose desloratadine and pseudoepedrine relieves moderate/severe nasal congestion in patients with seasonal allergic rhinitis (abstract). J Allergy Clin Immunol2002; 109 (2, pt 2): S103.
58.
BergerWE, the Desloratadine Study Group. Desloratadine reduces seasonal allergic rhinitis symptoms in patients with seasonal allergic rhinitis and asthma (abstract). J Allergy Clin Immunol2001; 107 (2, pt 2): S162.
59.
CorrenJ, the Desloratadine Study Group. Desloratadine reduces the use of inhaled beta 2-agonists and improves asthma symptoms in patients with seasonal allergic rhinitis and asthma (abstract). J Allergy Clin Immunol2001; 107 (2, pt 2): S163.
60.
RatnerPH, the Desloratadine Study Group. Desloratadine improved asthma symptoms and reduced bronchodilator use in 2 studies of patients with asthma and SAR (abstract). Ann Allergy Asthma Immunol2001; 86: 109:P63.
61.
DubuskeLM, the Desloratadine Study Group. Once-daily desloratadine reduces the symptoms of perennial allergic rhinitis for at least 4 weeks (abstract). J Allergy Clin Immunol2001; 107 (2, pt 2): S159.
62.
Data on file. Kenilworth, NJ: Schering Corporation.
RingJ, RudigerH, GaugerA, BronskyE, MillerB.Once-daily desloratadine improves the signs and symptoms of chronic idiopathic urticaria: a randomized, double-blind, placebo-controlled study. Int J Dermatol2001; 40: 1-5.
65.
BanfieldC, PadhiD, GlueP, HerronJM, StatkevichP, AffrimeMB. Electrocardiographic effects of multiple high doses of desloratadine (abstract). J Allergy Clin Immunol2001; 104 (1, pt 2): S383.
66.
KreutnerW, HeyJA, ChiuP, BarnettA.Preclinical pharmacology of desloratadine, a selective and nonsedating histamine H1 receptor antagonist. 2nd communication: lack of central nervous system and cardiovascular effects. Arzneimittelforschung2000; 50: 441-8.
67.
HeyJ, AnthesJ, BarnettA, TozziS, KreutnerW.Preclinical cardiovascular and CNS safety profile of desloratadine, a selective and nonsedating histamine H1-receptor antagonist (abstract). J Allergy Clin Immunol2001; 104 (1, pt 2): S383.
68.
ScharfMB, KayG, RikkenG.Desloratadine has no effect on wakefulness or psychomotor performance (abstract). Allergy2000; 55 (suppl 63): 280.
69.
RikkenG, ScharfMB, DanzigMR. Desloratadine and alcohol coadministration: no increase in impairment of performance over that induced by alcohol alone (abstract). Allergy2000; 55 (suppl 63): 277.
70.
NightingaleSL. From the US Food and Drug Administration. Warnings issued on nonsedating antihistamines terfenadine and astemizole. JAMA1992; 268: 705.
BanfieldC, HuntT, ReydermanL, StatkevicchP, PadhiD, AffrimeM.Lack of clinically relevant interaction between desloratadine and erythromycin. Clin Pharmacokinet2002; 41 (suppl 1): 20-35.
73.
BanfieldC, HerronJ, KeungA, PadhiD, AffrimeM.Desloratadine has no clinically relevant electrocardiographic or pharmacodynamic interactions with ketoconazole. Clin Pharmacokinet2002; 41 (suppl 1): 37-44.
74.
BanfieldC, GuptaS, KantesariaB.No drug interaction between fluoxetine and desloratadine, a new nonsedating once-daily antihistamine (abstract). J Allergy Clin Immunol2001; 107 (2, pt 2): S529.
75.
BrannanM, AffrimeM, CayenM.Effects of various cytochrome P450 inhibitors on the clearance of loratadine (L)/descarboethoxyloratadine (DCL) and lack of effects of increased L and DCL plasma concentrations on QTc intervals (abstract). Allergy1997; 37 (suppl 52): 207.
76.
GuptaS, BanfieldC, LimJ, MarinoM, ClementRP, AffrimeMB, et al. Unlike fexofenadine, the pharmacokinetics of desloratadine are minimally altered by coadministration with azithromycin (abstract). J Allergy Clin Immunol2001; 107 (2, pt2): S159.
77.
SoldnerA, ChristiansU, SusantoM, WacherVJ, SilvermanJA, BenetLZ. Grapefruit juice activates P-glycoprotein–mediated drug transport. Pharmaceutical Research1999; 16: 478-85.
78.
CayenM, WangE, ClementRP. Effect of desloratadine on P-glycoprotein transport system (MDR1) (abstract). Allergy2000;(suppl 63):S282.
79.
BanfieldC, SamirG, MarinoM, LimJ, AffrimeM.Grapefruit juice reduces the oral bioavailability of fexofenadine but not desloratadine. Clin Pharmacokinet2002; 41: 311-8.
80.
GuptaS, BanfieldC, AffrimeM, Marbury, PadhiD, GlueP.Oral bioavailability of desloratadine is unaffected by food. Clin Pharmacokinet2002;(suppl 1):7–12.
81.
AllegraClarinex, Claritin, Zyrtec. Drug topics red book. Montvale, NJ: Medical Economics Company, 2002.
HensleyS.Claritin's expected OTC switch may herald industry shake-up. The Wall Street Journal Online October 17, 2002 [accessed 2002 October 17]. Available from: URL: http://www.Online.wsj.com.
